

February 9, 2024
 SymBio Pharmaceuticals Limited
 Fuminori Yoshida
 Representative Director
 President and Chief Executive Officer
 (Securities Code: 4582)

**Notice of Recognition of Impairment Loss, and Differences between
 Consolidated Earnings Forecasts and Actual Results for FY2023**

SymBio Pharmaceuticals Limited (the “Company”), announced Notice of Recognition of Impairment Loss, and Differences between Consolidated Earnings Forecasts and Actual Results for FY2023 on February 8, 2024. This is to amend the amount of Ordinary profit of actual results and difference of Earnings Forecast for FY2023.

We also announce that no correction has been made to the Summary of Financial Statements for the Fiscal Year ending December 31 2023. The amendments are as follows (underlined):

Description

<Before the amendment>

2. Differences between Consolidated Earnings Forecast

(1) Earnings Forecast and Actual Results for FY2023 (January 1, 2023 to December 31, 2023)

	Net Sales	Operating Profit	Ordinary Profit	Profit attributable to owners of parent	Earnings per share
	Yen millions	Yen millions	Yen millions	Yen millions	Yen
Previous Forecast (A)	5,603	(680)	(549)	(1,291)	(32.53)
Actual Results (B)	5,589	(811)	<u>(736)</u>	(1,962)	(49.19)
Difference (B-A)	(13)	(132)	<u>(187S)</u>	(671)	—
Percentage Change (%)	(0.2)	—	—	—	—
[Reference] Prior Year Results (FY 2022)	10,008	1,963	1,999	1,179	30.20

(2) Reasons for Differences between Consolidated Earnings Forecast

The operating loss result of 811 million yen is greater than the loss previously forecasted, primarily due to quality issues in certain batches of TREAKISYM® that occurred in June 2023. An additional factor was an increase in general and administrative expenses due to higher R&D costs.

Ordinary loss is 728 million yen. The difference compared to the previous forecast is due to a

decrease in operating income and a decrease of 179 million yen due to the write-down of foreign currency denominated assets caused by the rapid appreciation of the yen from November 2023 to the end of the fiscal year.

Loss attributable to owners of parent is 1,962 million yen. The difference compared to the previous forecast is due to the impairment loss of 485 million yen on assets that is described in item 1 above.

<After the amendment>

2. Differences between Consolidated Earnings Forecast and Actual Results for FY 2023

(1) Earnings Forecast and Actual Result for FY 2023 (January 1, 2023 to December 31, 2023)

	Net Sales	Operating Profit	Ordinary Profit	Profit attributable to owners of parent	Earnings per share
	Yen millions	Yen millions	Yen millions	Yen millions	Yen
Previous Forecast (A)	5,603	(680)	(549)	(1,291)	(32.53)
Actual Results (B)	5,589	(811)	<u>(728)</u>	(1,962)	(49.19)
Difference (B-A)	(13)	(132)	<u>(179)</u>	(671)	—
Percentage Change (%)	(0.2)	—	—	—	—
[Reference] Prior Year Results (FY 2022)	10,008	1,963	1,999	1,179	30.20

(2) Reasons for Differences with Consolidated Earnings Forecast

The operating loss result of 811 million yen is greater than the loss previously forecasted, primarily due to quality issues in certain batches of TREAKISYM® that occurred in June 2023. An additional factor was an increase in general and administrative expenses due to higher R&D costs.

Ordinary loss is 728 million yen. The 179 million difference compared to the previous forecast is due to a decrease in operating income and a write-down of foreign currency denominated assets caused by the rapid appreciation of the yen from November 2023 to the end of the fiscal year.

Loss attributable to owners of parent is 1,962 million yen. The difference compared to the previous forecast is due to the impairment loss of 485 million yen on assets that is described in item 1 above.

[Contact]

Investor Relations

Tel: +81(0)3 5472 1125